Abstract
Mounting evidence suggests that copper may influence the progression of Alzheimers disease by reducing clearance of the amyloid beta protein (Aß) from the brain. We propose that Aβ is cleared from the brain by tagging along with cholesterol/ApoE in traversing the BBB, with subsequent incorporation into HDL for delivery of the toxin to the liver. It is suggested that either ABC-A1 or LRP, or both are involved in Aβ transport across the BBB, as well as normal cholesterol efflux. We have previously shown that addition of only 0.12 PPM copper (one-tenth the Environmental Protection Agency Human consumption limits) to distilled water was sufficient to precipitate the accumulation of Aß in the brains of cholesterol-fed rabbits. Here we show that in a setting of elevated cholesterol levels, overproduced Aβ is cleared to the blood and can simultaneously be identified in the liver if copper ion is absent from the animals drinking water, but if trace levels copper (0.12 PPM) are added to the drinking water Aβ accumulates in the brain, while the levels in the liver are greatly reduced.
Keywords: AD-like neuropathology, amyloid-beta, liver copper, ABCA1, LRP
Current Alzheimer Research
Title: Cholesterol Metabolism and Brain Amyloidosis: Evidence for a Role of Copper in the Clearance of A β Through the Liver
Volume: 4 Issue: 2
Author(s): D. Larry Sparks
Affiliation:
Keywords: AD-like neuropathology, amyloid-beta, liver copper, ABCA1, LRP
Abstract: Mounting evidence suggests that copper may influence the progression of Alzheimers disease by reducing clearance of the amyloid beta protein (Aß) from the brain. We propose that Aβ is cleared from the brain by tagging along with cholesterol/ApoE in traversing the BBB, with subsequent incorporation into HDL for delivery of the toxin to the liver. It is suggested that either ABC-A1 or LRP, or both are involved in Aβ transport across the BBB, as well as normal cholesterol efflux. We have previously shown that addition of only 0.12 PPM copper (one-tenth the Environmental Protection Agency Human consumption limits) to distilled water was sufficient to precipitate the accumulation of Aß in the brains of cholesterol-fed rabbits. Here we show that in a setting of elevated cholesterol levels, overproduced Aβ is cleared to the blood and can simultaneously be identified in the liver if copper ion is absent from the animals drinking water, but if trace levels copper (0.12 PPM) are added to the drinking water Aβ accumulates in the brain, while the levels in the liver are greatly reduced.
Export Options
About this article
Cite this article as:
Larry Sparks D., Cholesterol Metabolism and Brain Amyloidosis: Evidence for a Role of Copper in the Clearance of A β Through the Liver, Current Alzheimer Research 2007; 4 (2) . https://dx.doi.org/10.2174/156720507780362119
DOI https://dx.doi.org/10.2174/156720507780362119 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Obstructive Sleep Apnea Syndrome: From Phenotype to Genetic Basis
Current Genomics Nanostructured Lipid Carriers (NLCs): Nose-to-Brain Delivery and Theranostic Application
Current Drug Metabolism Meet Our Editorial Board Member
Current Neuropharmacology Influence of Betaine- and Choline-based Eutectic Solvents on Lipase Activity
Current Biochemical Engineering (Discontinued) Refractory Angina Pectoris: Lessons from the Past and Current Perspectives
Current Pharmaceutical Design The Fetal Origins of Obesity: Early Origins of Altered Food Intake
Endocrine, Metabolic & Immune Disorders - Drug Targets From the Prodrome to Chronic Schizophrenia: The Neurobiology Underlying Psychotic Symptoms and Cognitive Impairments
Current Pharmaceutical Design Glycine Transporter-1: A New Potential Therapeutic Target for Schizophrenia
Current Pharmaceutical Design Neurostimulation in Clinical and Sub-clinical Eating Disorders: A Systematic Update of the Literature
Current Neuropharmacology A New Frontier in the Treatment of Cancer: NK-1 Receptor Antagonists
Current Medicinal Chemistry The Importance of Citicoline in Combined Treatment in Dementia: What did the Citimem Study Teach us?
Reviews on Recent Clinical Trials Vitamin B<sub>12</sub> Deficiency Among the Healthy Jordanian Adult Population: Diagnostic Levels, Symptomology and Risk Factors
Endocrine, Metabolic & Immune Disorders - Drug Targets The Effects of Aging on Haptic Working Memory During Length Discrimination
Neuroscience and Biomedical Engineering (Discontinued) Glia-Driven Neuroinflammation and Systemic Inflammation in Alzheimer’s Disease
Current Neuropharmacology Thalidomide: A Banned Drug Resurged into Future Anticancer Drug
Current Drug Therapy Current Status and Future Prospects of Small–molecule Protein–protein Interaction (PPI) Inhibitors of Tumor Necrosis Factor (TNF) and Receptor Activator of NF-κB Ligand (RANKL)
Current Topics in Medicinal Chemistry Heart Rate Variability Analysis at Coronary Artery Disease and Angina Pectoris
Recent Patents on Cardiovascular Drug Discovery Polyunsaturated Fatty Acids in Pathological Retinal Angiogenesis
Current Nutrition & Food Science Toxin-Labeled Monoclonal Antibodies
Current Pharmaceutical Biotechnology Music Therapy in the Management of Dementia
Current Psychiatry Research and Reviews